By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
Business of developing and commercializing genome editing technology2.83M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States40.52M100.00%